What's the next best cytokine target in IBD?

MacDonald, Thomas T, Biancheri, Paolo, Sarra, Massimiliano and Monteleone, Giovanni (2012) What's the next best cytokine target in IBD? Inflammatory Bowel Diseases, 18 (11). pp. 2180-2189. ISSN 1078-0998

Full text not available from this repository. (Request a copy)

Abstract

In the gut of patients with inflammatory bowel disease (IBD), immune and nonimmune cells produce large amounts of cytokines that drive the inflammatory process leading to the tissue damage. Cytokine blockers, such as anti-tumor necrosis factor alpha (TNF-α), have been used with some success in IBD. However, not all patients respond, and the therapeutic effects wane with time, demonstrating the need for more effective and long-lasting antiinflammatory strategies. A key question is whether neutralizing other proinflammatory cytokines such as interleukin (IL)-12, IL-21, IL-27, or IL-33 will lead to a better clinical response than with anti-TNF-α antibodies. Equally, we now know that IBD-related inflammation is marked by defective production/activity of antiinflammatory cytokines, and there are strategies to correct these defects. An alternative approach is to try to target individual therapies to individual patients, to improve clinical efficacy in subsets of patients, but this has proven difficult. Here we try to evaluate the potential of each of these choices.

Item Type: Article
Additional Information: Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Uncontrolled Keywords: therapeutic use,antagonists & inhibitors,humans,drug therapy
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 07 Aug 2018 17:30
Last Modified: 05 Feb 2019 16:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/67984
DOI: 10.1002/ibd.22967

Actions (login required)

View Item